Table 1.

FDA-approved treatment regimen for blockade of the PD-1/PD-L1 axis in tumor therapy.

FDA Approval	PD-1 Antibody	PD-L1 Antibody	References
Advanced and metastatic melanoma	Nivolumab Pembrolizumab		[99] [101]
Metastatic Merkel cell carcinoma		Avelumab	[104]
Advanced cutaneous squamous cell carcinoma	Cemiplimab		[102]
Locally advanced or metastatic urothelial carcinoma	Nivolumab Pembrolizumab	Atezolizumab Durvalumab	[105,106,107,108,109,110]
Metastatic non-small-cell lung cancer (NSCLC)	Nivolumab Pembrolizumab	Atezolizumab Durvalumab	[43,111,112,113,114,115,116]
Metastatic small cell lung cancer	Nivolumab	Atezolizumab	[43,116]
Metastatic pleural mesothelioma	Nivolumab		[117]
Advanced or metastatic renal cell carcinoma	Nivolumab		[118]
Unresectable, locally advanced or metastatic triple-negative breast cancer		Atezolizumab	[44]
Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation	Nivolumab Pembrolizumab		[119] [120,121]
Metastatic or recurrent head and neck squamous cell carcinoma	Nivolumab Pembrolizumab		[122] [123]
Locally advanced or metastatic human epidermal growth factor receptor 2+ gastric cancer	Pembrolizumab		[124]
Hepatocellular carcinoma (HCC)	Nivolumab		[125]
Microsatellite instability-high or mismatch repair deficient metastatic CRC	Nivolumab		[45]
	Pembrolizumab		[126,127]
Locally advanced or metastatic esophageal cancer that relapsed on prior therapy	Nivolumab Pembrolizumab		[128] [129]